Gao-jun Teng, M.D
Zhongda hospital, Southeast university, Nanjing, China
5
5
2
N/A
0
6
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
No phase data
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Jinbo Yue, Doctor
Shandong Cancer Hospital and Institute
Shared therapeutic areas:
Yao Xie, Doctor
Beijing Ditan Hospital
Shared therapeutic areas:
guibin Qiao, MD
Guangdong Provincial People's Hospital
Shared therapeutic areas:
Yan Sun, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Worked with same sponsors:
Yun-fei Xia, MD
Sun Yat-sen University
Shared therapeutic areas:
Jun Huang, MD
Sixth Affiliated Hospital, Sun Yat-sen University
Shared therapeutic areas:
Tsang-Wu Liu
Taiwan Cooperative Oncology Group, NHRI
Shared therapeutic areas:
Ming Kuang, PhD
First Affiliated Hospital, Sun Yat-Sen University
Shared therapeutic areas:
Donald Leung, MD, PhD
National Jewish Health
Shared therapeutic areas:
Shuhang Wang
NCC, CICAMS
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions
All 5 trials loaded